• 1
    Argyris E.G., Kulkosky J., Meyer M.E., Xu Y., Mukhtar M., Pomerantz R.J., Williams K.J. (2004) The perlecan heparan sulfate proteoglycan mediates cellular uptake of HIV-1 Tat through a pathway responsible for biological activity. Virology;330:481486.
  • 2
    Caron N.J., Quenneville S.P., Tremblay J.P. (2004) Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochem Biophys Res Commun;319:1220.
  • 3
    Console S., Marty C., Garcia-Echeverria C., Schwendener R., Ballmer-Hofer K. (2003) Antennapedia and HIV transactivator of transcription (TAT) “protein transduction domains” promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem;278:3510935114.
  • 4
    Geisler I., Chmielewski J. (2007) Probing length effects and mechanism of cell penetrating agents mounted on a polyproline helix scaffold. Bioorg Med Chem Lett;17:27652768.
  • 5
    Vives E., Brodin P., Lebleu B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem;272:1601016017.
  • 6
    Licht T., Tsirulnikov L., Reuveni H., Yarnitzky T., Ben-Sasson S.A. (2003) Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood;102:20992107.
  • 7
    Mukherjee S., Palczewski K., Gurevich V.V., Hunzicker-Dunn M. (1999) Beta-arrestin-dependent desensitization of luteinizing hormone/choriogonadotropin receptor is prevented by a synthetic peptide corresponding to the third intracellular loop of the receptor. J Biol Chem;274:1298412989.
  • 8
    Wess J. (1997) G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J;11:346354.
  • 9
    Bonny C., Oberson A., Negri S., Sauser C., Schorderet D.F. (2001) Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes;50:7782.
  • 10
    Gupta B., Levchenko T.S., Torchilin V.P. (2005) Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev;57:637651.
  • 11
    Lin Y.Z., Yao S.Y., Veach R.A., Torgerson T.R., Hawiger J. (1995) Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem;270:1425514258.
  • 12
    Lindgren M., Hallbrink M., Prochiantz A., Langel U. (2000) Cell-penetrating peptides. Trends Pharmacol Sci;21:99103.
  • 13
    Mae M., Langel U. (2006) Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol;6:509514.
  • 14
    Rojas M., Yao S., Lin Y.Z. (1996) Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem;271:2745627461.
  • 15
    Wang J.L., Zhang Z.J., Choksi S., Shan S., Lu Z., Croce C.M. et al. (2000) Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res;60:14981502.
  • 16
    Yu J., Taylor L., Mierke D., Berg E., Shia M., Fishman J. et al. (2010) Limiting angiotensin II signaling with a cell-penetrating peptide mimicking the second intracellular loop of the angiotensin II type-I receptor. Chem Biol Drug Des;76:7076.
  • 17
    Galie N., Manes A., Branzi A. (2004) The endothelin system in pulmonary arterial hypertension. Cardiovasc Res;61:227237.
  • 18
    Miyauchi T., Masaki T. (1999) Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol;61:391415.
  • 19
    Filep J.G., Foldes-Filep E., Rousseau A., Sirois P., Fournier A. (1993) Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat. Br J Pharmacol;110:12131221.
  • 20
    de Nucci G., Thomas R., D’Orleans-Juste P., Antunes E., Walder C., Warner T.D., Vane J.R. (1988) Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA;85:97979800.
  • 21
    Comhair S.A., Xu W., Mavrakis L., Aldred M.A., Asosingh K., Erzurum S.C. (2012) Human primary lung endothelial cells in culture. Am J Respir Cell Mol Biol;Mar 15. [Epub ahead of print].
  • 22
    Liu B., Yu J., Taylor L., Zhou X., Polgar P. (2006) Microarray and phosphokinase screenings leading to studies on ERK and JNK regulation of connective tissue growth factor expression by angiotensin II 1a and bradykinin B2 receptors in Rat1 fibroblasts. J Cell Biochem;97:11041120.
  • 23
    Zhou X., Prado G.N., Taylor L., Yang X., Polgar P. (2000) Regulation of inducible bradykinin B1 receptor gene expression through absence of internalization and resensitization. J Cell Biochem;78:351362.
  • 24
    Aramori I., Nakanishi S. (1992) Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. J Biol Chem;267:1246812474.
  • 25
    Sugawara F., Ninomiya H., Okamoto Y., Miwa S., Mazda O., Katsura Y. et al. (1996) Endothelin-1-induced mitogenic responses of Chinese hamster ovary cells expressing human endothelinA: the role of a wortmannin-sensitive signaling pathway. Mol Pharmacol;49:447457.
  • 26
    Afonin S., Frey A., Bayerl S., Fischer D., Wadhwani P., Weinkauf S. et al. (2006) The cell-penetrating peptide TAT(48-60) induces a non-lamellar phase in DMPC membranes. ChemPhysChem;7:21342142.
  • 27
    Duchardt F., Fotin-Mleczek M., Schwarz H., Fischer R., Brock R. (2007) A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic;8:848866.
  • 28
    Gump J.M., Dowdy S.F. (2007) TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med;13:443448.
  • 29
    Barysch S.V., Jahn R., Rizzoli S.O. (2010) A fluorescence-based in vitro assay for investigating early endosome dynamics. Nat Protoc;5:11271137.
  • 30
    Hall H., Williams E.J., Moore S.E., Walsh F.S., Prochiantz A., Doherty P. (1996) Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide. Curr Biol;6:580587.
  • 31
    Liu X.Y., Timmons S., Lin Y.Z., Hawiger J. (1996) Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs. Proc Natl Acad Sci USA;93:1181911824.
  • 32
    Torgerson T.R., Colosia A.D., Donahue J.P., Lin Y.Z., Hawiger J. (1998) Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol;161:60846092.
  • 33
    McCulloch D.A., MacKenzie C.J., Johnson M.S., Robertson D.N., Holland P.J., Ronaldson E. et al. (2002) Additional signals from VPAC/PAC family receptors. Biochem Soc Trans;30:441446.
  • 34
    Morou E., Georgoussi Z. (2005) Expression of the third intracellular loop of the delta-opioid receptor inhibits signaling by opioid receptors and other G protein-coupled receptors. J Pharmacol Exp Ther;315:13681379.
  • 35
    Evans N.J., Walker J.W. (2008) Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization. Biophys J;95:483492.
  • 36
    Evans N.J., Walker J.W. (2008) Sustained Ca2+ signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. Can J Physiol Pharmacol;86:526535.
  • 37
    Gregan B., Jurgensen J., Papsdorf G., Furkert J., Schaefer M., Beyermann M. et al. (2004) Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem;279:2767927687.
  • 38
    Harada N., Himeno A., Shigematsu K., Sumikawa K., Niwa M. (2002) Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: possible formation of an ETA-ETB receptor heterodimer. Cell Mol Neurobiol;22:207226.